Pharma Capital

e-Therapeutics 'purposefully going out to the world' to engage with big pharma

Ray Barlow, chief executive of e-Therapeutics plc (LON:ETX) caught up with Proactive to update on developments at the drug developer.

Last month they unveiled the results of its strategic review under the new chief executive.

Following the review, the company decided to invest in its network-driven drug discovery (NDD) platform in creating new drugs, while continuing to control costs.

''The first three months of my tenure have been internally-facing .. we're now very purposefully going out to the world'', Barlow says.

''We're going to undertake a very  systematic business development exercise, we're going to engage with biopharmaceutical companies ... we're also going to engage with companies that may not be traditionally associated with this space - such as the googles of this world''.

 

View full ETX profile

e-Therapeutics plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.